Ascendis Pharma A/S A71.F Stock
Ascendis Pharma A/S Price Chart
Ascendis Pharma A/S A71.F Financial and Trading Overview
| Ascendis Pharma A/S stock price | 141 EUR |
| Previous Close | 98.5 EUR |
| Open | 98.5 EUR |
| Bid | 0 EUR x 100000 |
| Ask | 0 EUR x 100000 |
| Day's Range | 98.5 - 98.5 EUR |
| 52 Week Range | 74.5 - 127 EUR |
| Volume | 10 EUR |
| Avg. Volume | 0 EUR |
| Market Cap | 5.54B EUR |
| Beta (5Y Monthly) | 0.516197 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -8.54 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 193.5 EUR |
A71.F Valuation Measures
| Enterprise Value | 5.46B EUR |
| Trailing P/E | N/A |
| Forward P/E | -10.144181 |
| PEG Ratio (5 yr expected) | -0.64 |
| Price/Sales (ttm) | 71.04917 |
| Price/Book (mrq) | 33.120377 |
| Enterprise Value/Revenue | 70.018 |
| Enterprise Value/EBITDA | -9.547 |
Trading Information
Ascendis Pharma A/S Stock Price History
| Beta (5Y Monthly) | 0.516197 |
| 52-Week Change | 32.21% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 127 EUR |
| 52 Week Low | 74.5 EUR |
| 50-Day Moving Average | 98.59 EUR |
| 200-Day Moving Average | 106.04 EUR |
A71.F Share Statistics
| Avg. Volume (3 month) | 0 EUR |
| Avg. Daily Volume (10-Days) | 0 EUR |
| Shares Outstanding | 56.22M |
| Float | 55.87M |
| Short Ratio | N/A |
| % Held by Insiders | 0.073% |
| % Held by Institutions | 123.56% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -740.96% |
| Gross Margin | 83.94% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -30.80% |
| Return on Equity (ttm) | -135.38% |
Income Statement
| Revenue (ttm) | 77.94M EUR |
| Revenue Per Share (ttm) | 1.39 EUR |
| Quarterly Revenue Growth (yoy) | 391.89% |
| Gross Profit (ttm) | 39.04M EUR |
| EBITDA | -571564992 EUR |
| Net Income Avi to Common (ttm) | -568609984 EUR |
| Diluted EPS (ttm) | -10.17 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 585.74M EUR |
| Total Cash Per Share (mrq) | 10.42 EUR |
| Total Debt (mrq) | 505.38M EUR |
| Total Debt/Equity (mrq) | 302.26 EUR |
| Current Ratio (mrq) | 4.083 |
| Book Value Per Share (mrq) | 2.974 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -511955008 EUR |
| Levered Free Cash Flow (ttm) | -316446624 EUR |
Profile of Ascendis Pharma A/S
| Country | Germany |
| State | N/A |
| City | Hellerup |
| Address | Tuborg Boulevard 12 |
| ZIP | 2900 |
| Phone | 45 70 22 22 44 |
| Website | https://ascendispharma.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 797 |
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company also develops TransCon Growth Hormone for treating pediatric GHD, adult GHD, and turner syndrome; TransCon Parathyroid Hormone for adult patients with hypoparathyroidism; and TransCon C-type natriuretic peptide for achondroplasia. In addition, it is developing TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/? for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
Q&A For Ascendis Pharma A/S Stock
What is a current A71.F stock price?
Ascendis Pharma A/S A71.F stock price today per share is 141 EUR.
How to purchase Ascendis Pharma A/S stock?
You can buy A71.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Ascendis Pharma A/S?
The stock symbol or ticker of Ascendis Pharma A/S is A71.F.
Which industry does the Ascendis Pharma A/S company belong to?
The Ascendis Pharma A/S industry is Biotechnology.
How many shares does Ascendis Pharma A/S have in circulation?
The max supply of Ascendis Pharma A/S shares is 56.61M.
What is Ascendis Pharma A/S Price to Earnings Ratio (PE Ratio)?
Ascendis Pharma A/S PE Ratio is now.
What was Ascendis Pharma A/S earnings per share over the trailing 12 months (TTM)?
Ascendis Pharma A/S EPS is -8.54 EUR over the trailing 12 months.
Which sector does the Ascendis Pharma A/S company belong to?
The Ascendis Pharma A/S sector is Healthcare.